Functions and application of activin receptor-like kinase 4 in treatment of cardiac hypertrophy

A technology for cardiac hypertrophy and cardiac function, applied to the function and application of activin receptor-like kinase 4 in the treatment of cardiac hypertrophy, the application of drugs for alleviating and/or treating cardiac hypertrophy, and the field of preparation and prevention, which can solve the problems that have not yet been seen in ALK4 To achieve the effect of inhibiting myocardial hypertrophy and improving heart function

Inactive Publication Date: 2017-03-22
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on the role of ALK4 in cardiovascular diseases, especially in cardiac hypertrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Functions and application of activin receptor-like kinase 4 in treatment of cardiac hypertrophy
  • Functions and application of activin receptor-like kinase 4 in treatment of cardiac hypertrophy
  • Functions and application of activin receptor-like kinase 4 in treatment of cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] [Example 1] Effect of ALK4 interference (AdshALK4) and overexpression (AdALK4) adenovirus on Ang II-stimulated primary cardiomyocyte hypertrophy

[0056] 1. Primary neonatal SD rat cardiomyocyte culture

[0057] (1) Eight newborn Sprague-Dawley suckling mice were disinfected with 75% alcohol below the neck, and the heart was removed with ophthalmic scissors and micro forceps, and placed in a glass plate filled with 10mL DMEM / F12 solution. Take another one and repeat the above process.

[0058] (2) Wash the heart with DMEM / F12 medium, and cut the heart into 1-2mm 3 fragments. Transfer to a serum bottle with a rotor, suck off DMEM / F12, and add trypsin digestion solution. Rotate at 120r / min, digest for 15min, rest for a few seconds, and discard the supernatant.

[0059] (3) Add trypsin digestion solution, the rotation speed is 120r / min, and digest for 15min. Stand still for a few seconds, draw the supernatant, terminate the digestion with DMEM / F12 medium with 20% calf...

Embodiment 2

[0076] [Example 2] Construction of heart-specific ALK4 knockout mice and ALK4 transgenic mice:

[0077] (1) Construction of cardiac-specific ALK4 gene knockout mice (see figure 2 A):

[0078] According to gene information, using CRISPR Design (URL: http: / / crispr.mit.edu / ) to design a CRISPR targeting site in intron 1 and 2 respectively. The target sequences are:

[0079] ALK4-sgRNA 1: ggTCCATCCAAATGGGTCCTGC TGG

[0080] ALK4-sgRNA2: ggCTCAGGGCATGAAGCGTTTT TGG

[0081] In addition, a donor plasmid (Donor Vector) for homology repair was designed, which includes homology arms on both sides, exons 2 and 3 in the middle, and two loxp sequences in the same direction.

[0082] ①Construction of targeting vector: The two primers corresponding to sgRNA1 and sgRNA2 were respectively fused into double-stranded DNA, and then ligated into pUC57-sgRNA vector treated with restriction endonuclease BsaI with T4 DNA ligase. There is a T7 promoter upstream of the vector, which can be use...

Embodiment 3

[0103] [Example 3] Myocardial hypertrophy model acquisition

[0104] 1. Grouping of experimental animals: male background C57BL / 6 cardiac-specific Cre mice (α-MHC-Cre (WT), cardiac-specific ALK4 knockout mice (ALK4-KO) and cardiac-specific ALK4 transgenic mice ( TG) and non-transgenic mice (NTG), through aortic constriction (AB) to establish myocardial hypertrophy model. Randomly divided into 8 groups, grouped as follows: C57BL / 6 background wild-type mice sham operation group (WT Sham) and AB operation group (WT AB), ALK4 knockout mouse sham operation group (ALK4-KOSham) and AB operation group (ALK4-KO AB), non-transgenic mouse sham operation group (NTG Sham) and AB operation group (NTG AB), heart-specific ALK4 transgenic mouse sham operation group (TG Sham) and AB operation group (TG AB).

[0105] 2. The myocardial hypertrophy model adopts aortic arch coarctation (AB) surgery, and the operation process of the model is as follows:

[0106] 2.1 Preoperative preparation

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses functions and application of activin receptor-like kinase 4 (ALK4) in treatment of cardiac hypertrophy. The ALK4 has the functions of restraining cardiac hypertrophy and fibrosis thereof and improving the cardiac function in a cardiac hypertrophy model caused by an aortic coarctation operation and Ang II stimulation. Accordingly, an ALK4 gene can be used as a medicine target to be applied to screening of medicine for protecting the cardiac function, resisting cardiac fibrosis and/or preventing, relieving and/or treating cardiac hypertrophy. The ALK4 can be used for preparing the medicine for protecting the cardiac function, resisting cardiac fibrosis and/or preventing, relieving and/or treating cardiac hypertrophy, and a new path for treating cardiac hypertrophy is provided.

Description

technical field [0001] The invention belongs to the field of gene function and application, in particular to the function and application of Activin Receptor-like Kinase 4 (Activin Receptor-like Kinase 4, ALK4) in the treatment of cardiac hypertrophy, specifically in the preparation of prevention, relief and / or Application of drugs in the treatment of cardiac hypertrophy. Background technique [0002] Myocardial hypertrophy is an adaptive compensatory response of myocardial cells to the stimulation of neurohumoral factors and changes in mechanical stress load. It is a complex and dynamic process that incorporates many factors involved in regulation. Cardiomyopathy, cardiomyopathy and other common pathological processes that need to be experienced in the development of most cardiovascular diseases[1]. Myocardial hypertrophy is an adaptive compensatory response of the heart to various cardiovascular stimuli such as hemodynamic load, angiotensin, growth factors, and hormones, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/45A61K48/00C12Q1/02A61P9/00A61P9/04
CPCA61K38/45A61K48/005C12N2503/02G01N33/5061G01N2500/10
Inventor 李红良陈曼华向梅邓克穷
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap